Belite Bio (BLTE) Expected to Post Earnings on Monday

Belite Bio (NASDAQ:BLTE) will likely be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.7863) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE) last issued its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share (EPS) for the quarter. On average, analysts expect Belite Bio to post ($3.08) EPS for the current fiscal year and $0.91 EPS for the next fiscal year.

Belite Bio Stock Performance

Belite Bio stock opened at $154.74 on Monday. Belite Bio has a 52 week low of $97.99 and a 52 week high of $200.00. The stock has a market capitalization of $6.23 billion, a P/E ratio of -56.68 and a beta of -1.19. The stock has a 50-day simple moving average of $161.47 and a 200 day simple moving average of $160.37.

Insider Activity

In other news, CEO Yu-Hsin Lin sold 74,435 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $187.71, for a total transaction of $13,972,193.85. Following the transaction, the chief executive officer owned 96,134 shares in the company, valued at approximately $18,045,313.14. This trade represents a 43.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Hendrik Scholl sold 500 shares of Belite Bio stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $165.32, for a total value of $82,660.00. Following the sale, the insider directly owned 14,500 shares of the company’s stock, valued at approximately $2,397,140. The trade was a 3.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 169,062 shares of company stock valued at $32,101,134. 13.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BLTE has been the topic of several research analyst reports. Jefferies Financial Group restated a “hold” rating on shares of Belite Bio in a research note on Wednesday, September 9th. Morgan Stanley boosted their target price on Belite Bio from $201.00 to $206.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Benchmark reissued a “buy” rating on shares of Belite Bio in a report on Friday, August 14th. Cantor Fitzgerald increased their price target on Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Canaccord Genuity Group assumed coverage on Belite Bio in a report on Friday, September 4th. They set a “buy” rating and a $303.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Belite Bio presently has an average rating of “Moderate Buy” and a consensus target price of $227.40.

Belite Bio Company Profile

Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for eye diseases that can cause severe vision loss. The company’s research is centered on therapies that target the visual cycle, a biological process involved in the production and recycling of vitamin A in the retina.

Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. The orally administered therapy is designed to reduce the formation and accumulation of toxic vitamin A byproducts in the eye.